Mapping molecular networks using proteomics: A vision for patient-tailored combination therapy

被引:119
作者
Petricoin, EF
Bichsel, VE
Calvert, VS
Espina, V
Winters, M
Young, L
Belluco, C
Trock, BJ
Lippman, M
Fishman, DA
Sgroi, DC
Munson, PJ
Esserman, LJ
Liotta, LA
机构
[1] NCI, US FDA, Clin Prote Program, Off Cellular & Gene Therapy,CBER, Bethesda, MD 20892 USA
[2] NCI, US FDA, Clin Prote Program, Pathol Lab,Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[3] NIH, Biostat Sect, Math & Stat Comp Lab, Ctr Informat Technol, Bethesda, MD 20892 USA
[4] Johns Hopkins Univ, Dept Urol, Baltimore, MD USA
[5] Univ Padua, Dept Oncol & Surg Sci, Padua, Italy
[6] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[7] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA
[8] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA
[9] Harvard Univ, Sch Med, Charlestown, MA USA
[10] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[11] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2005.02.509
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mapping tumor cell protein networks in vivo will be critical for realizing the promise of patient-tailored molecular therapy. Cancer can be defined as a dysregulation or hyperactivity in the network of intracellular and extracellular signaling cascades. These protein signaling circuits are the ultimate targets of molecular therapy. Each patient's tumor may be driven by a distinct series of molecular pathogenic defects. Thus, for any single molecular targeted therapy, only a subset of cancer patients may respond. Individualization of therapy, which tailors a therapeutic regimen to a tumor molecular portrait, may be the solution to this dilemma. Until recently, the field lacked the technology for molecular profiling at the genomic and proteomic level. Emerging proteomic technology, used concomitantly with genomic analysis, promises to meet this need and bring to reality the clinical adoption of molecular stratification. The activation state of kinase-driven signal networks contains important information relative to cancer pathogenesis and therapeutic target selection. Proteomic technology offers a means to quantify the state of kinase pathways, and provides post-translational phosphorylation data not obtainable by gene arrays. Case studies using clinical research specimens are provided to show the feasibility of generating the critical information needed to individualize therapy. Such technology can reveal potential new pathway interconnections, including differences between primary and metastatic lesions. We provide a vision for individualized combinatorial therapy based on proteomic mapping of phosphorylation end points in clinical tissue material. (c) 2005 by American Society of Clinical Oncology.
引用
收藏
页码:3614 / 3621
页数:8
相关论文
共 60 条
[41]  
Nishizuka S, 2003, CANCER RES, V63, P5243
[42]   Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome [J].
Oda, Y ;
Nagasu, T ;
Chait, BT .
NATURE BIOTECHNOLOGY, 2001, 19 (04) :379-382
[43]   EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].
Paez, JG ;
Jänne, PA ;
Lee, JC ;
Tracy, S ;
Greulich, H ;
Gabriel, S ;
Herman, P ;
Kaye, FJ ;
Lindeman, N ;
Boggon, TJ ;
Naoki, K ;
Sasaki, H ;
Fujii, Y ;
Eck, MJ ;
Sellers, WR ;
Johnson, BE ;
Meyerson, M .
SCIENCE, 2004, 304 (5676) :1497-1500
[44]   Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front [J].
Paweletz, CP ;
Charboneau, L ;
Bichsel, VE ;
Simone, NL ;
Chen, T ;
Gillespie, JW ;
Emmert-Buck, MR ;
Roth, MJ ;
Petricoin, EF ;
Liotta, LA .
ONCOGENE, 2001, 20 (16) :1981-1989
[45]   Regulation and targets of receptor tyrosine kinases [J].
Pawson, T .
EUROPEAN JOURNAL OF CANCER, 2002, 38 :S3-S10
[46]  
Pegram M D, 2000, Cancer Treat Res, V103, P57
[47]   Clinical proteomics: Translating benchside promise into bedside reality [J].
Petricoin, EF ;
Zoon, KC ;
Kohn, EC ;
Barrett, JC ;
Liotta, LA .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :683-695
[48]   High frequency of mutations of the PIK3CA gene in human cancers [J].
Samuels, Y ;
Wang, ZH ;
Bardelli, A ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Yan, H ;
Gazdar, A ;
Powell, DM ;
Riggins, GJ ;
Willson, JKV ;
Markowitz, S ;
Kinzler, KW ;
Vogelstein, B ;
Velculescu, VE .
SCIENCE, 2004, 304 (5670) :554-554
[49]   Smart drugs: Tyrosine kinase inhibitors in cancer therapy [J].
Shawver, LK ;
Slamon, D ;
Ullrich, A .
CANCER CELL, 2002, 1 (02) :117-123
[50]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792